A single-session brain, heart and bone F-18 FDG-PET/MRI scan identified a significant link between cumulative chemotherapy doses and MRI measures of left ventricular ejection fraction and end-systolic volume, but not brain or bone abnormality severity, in pediatric cancer survivors, while those treated with methotrexate had substantially lower cerebral blood flow and metabolic activity in major brain regions than controls. The findings, published in the journal Radiology, suggest the approach may prompt earlier detection of chemo-induced tissue injuries and help improve long-term health of pediatric cancer survivors, researchers said.
Pediatric cancer survivors may benefit from triple-organ F-18 FDG-PET/MRI
Sign up for ANA SmartBrief
Nursing news and information
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.